Oruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Several other analysts have also recently weighed in on ORKA. BTIG Research began coverage on shares of Oruka Therapeutics in a research report on Thursday, May 22nd. They set a “buy” rating on the stock. Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $40.38.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $12.56 on Friday. The company’s 50 day simple moving average is $10.28 and its two-hundred day simple moving average is $13.07. The stock has a market capitalization of $470.26 million, a PE ratio of -2.01 and a beta of -0.38. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. On average, research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics in the 4th quarter worth $54,000. AlphaCentric Advisors LLC purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $119,000. Squarepoint Ops LLC purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $236,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $303,000. Finally, AlphaQuest LLC purchased a new position in shares of Oruka Therapeutics in the first quarter valued at about $168,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.